A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous canc...
A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Inhibition of programmed death 1 (PD-1), expressed on activated T cells, can break through immune resistance and elicit durable responses in human melanoma as well as other types of cancers. Canine oral malignant melanoma is one of the most aggressive tumors bearing poor prognosis due to its high metastatic potency. However, there are few effective...
Alternative Titles
Full title
A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_7ea57068e99f4b3d9f9d8844f0926591
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7ea57068e99f4b3d9f9d8844f0926591
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-020-75533-4
